Ylä-Herttuala S
A.I. Virtanen Institute, University of Kuopio, Finland.
Curr Opin Lipidol. 1997 Apr;8(2):72-6. doi: 10.1097/00041433-199704000-00004.
Vascular gene transfer may be useful for the treatment of several cardiovascular diseases. It can also be used as an experimental tool to test the effects of various genes in a local vascular compartment. Promising therapeutic effects have been obtained in animal models of restenosis with the transfer of vascular endothelial growth factor, nitric oxide synthase, thymidine kinase, retinoblastoma, growth arrest homeobox gene, cyclin/cyclin-dependent kinase inhibitor (p21), and hirudin genes, and antisense oligonucleotides against transcription factors or cell cycle regulatory proteins. Vascular endothelial growth factor and fibroblast growth factor gene transfers have improved blood flow and capillary development in models of ischaemic limb and myocardium. First experiences of vascular endothelial growth factor gene transfer to human peripheral arteries have also been reported. However, further developments in gene delivery techniques and gene transfer vectors will be required before a full therapeutic potential of gene therapy in cardiovascular diseases can be evaluated.
血管基因转移可能对多种心血管疾病的治疗有用。它还可作为一种实验工具，用于测试各种基因在局部血管腔室中的作用。通过转移血管内皮生长因子、一氧化氮合酶、胸苷激酶、视网膜母细胞瘤、生长停滞同源框基因、细胞周期蛋白/细胞周期蛋白依赖性激酶抑制剂（p21）和水蛭素基因，以及针对转录因子或细胞周期调节蛋白的反义寡核苷酸，在再狭窄动物模型中已获得了有前景的治疗效果。血管内皮生长因子和成纤维细胞生长因子基因转移改善了缺血肢体和心肌模型中的血流和毛细血管发育。也有关于血管内皮生长因子基因转移至人外周动脉的初步经验报道。然而，在能够评估基因治疗在心血管疾病中的全部治疗潜力之前，还需要在基因递送技术和基因转移载体方面取得进一步进展。
